

Single Day Event

Use of eCOA in Clinical Trials – Programmers' Perspective

Deepthi BM, GSK



Disclaimer

The opinions expressed in this presentation and on the following slides are solely those of the presenter and not necessarily those of GSK. GSK does not guarantee the accuracy or reliability of the information provided herein.




Agenda

- What are eCOA?
- Applicability of eCOA
- eCOA Setup Process
- eCOA Project Planning
- Data Scenarios
- Missing Data
- Regulatory Consideration



What are eCOA?

Clinical Outcome Assessment – Assess clinical outcome evaluated by a clinician, a patient, a non-clinician observer or through performance based⁽¹⁾





Applicability of eCOA

Under each heading, please tick the ONE that best describes your health TODAY.

MOBILITY

I have no problems in walking about ☒ **A**

I have slight problems in walking about ☐ **B**

I have moderate problems in walking about ☐ **C**

I have severe problems in walking about ☐ **D**

I am unable to walk about ☐ **E**

Cardiovascular

I feel myself ☐ **A**

I am tired of myself ☐ **B**

I am tired of myself ☐ **C**

I am tired of myself ☐ **D**

I am tired of myself ☐ **E**

Cancer

I am unable to do my usual activities ☐ **A**

I am unable to do my usual activities ☐ **B**

I am unable to do my usual activities ☐ **C**

I am unable to do my usual activities ☐ **D**

I am unable to do my usual activities ☐ **E**

Diabetes

I have no problems in walking about ☐ **A**

I have slight problems in walking about ☐ **B**

I have moderate problems in walking about ☐ **C**

I have severe problems in walking about ☐ **D**

I am unable to walk about ☐ **E**

Kidney Disease

I am not anxious or depressed ☐ **A**

I am slightly anxious or depressed ☐ **B**

I am moderately anxious or depressed ☐ **C**

I am severely anxious or depressed ☐ **D**

I am extremely anxious or depressed ☐ **E**

VS

CNS

Respiratory

CHRONIC DISEASE

01. How sleepy did you feel before taking the drug?

0 1 2 3 4 5 6 7 8 9 10

Not sleep at all Struggling to stay awake

02. How well did you sleep after taking the drug?

0 1 2 3 4 5 6 7 8 9 10

Not sleep at all Struggling to stay awake

03. Are you satisfied with the effect of the drug taken?


0 1 2 3 4 5 6 7 8 9 10

Not sleep at all Struggling to stay awake

04. Anything else you have noticed and want to report?

Submit

eCOA Setup Process – High Level



 Programmers should be involved and consulted

 Possible areas, if not well conducted, impact programming

eCOA Project Planning – Involvement of Programmer

- ❖ It is important to initiate the eCOA data workflow planning while protocol development is happening

- ❖ Involvement of cross functional team in eCOA planning is essential

- ❖ All necessary team should participate in eCOA workflow planning from the start stone and timelines


Is the data collection specified meets the analyses requirement?

How are the visits / ad-hoc visits handled? How about unscheduled visit?

Are the timepoints correctly captured for daily diary data, meeting analyses requirement?

Should we implement eCOA for this assessment?

Will the design cause missing data and what steps taken to minimize them?





Data Scenario 1 – Impact to visit slotting algorithm

qs.xpt

SUBJID	VISITNUM	QSTESTCD	QSORRES	QSDTC
1001	20	ACQ-01	3	2021-10-10
1001	20	ACQ-02	2	2021-10-10
1001	20	ACQ-03	4	2021-10-10
1001	20	ACQ-04	3	2021-10-10
1001	20	ACQ-05	3	2021-10-10

ACQ-5 assessment is performed at each visit with a +/- 2 days window period

sv.xpt

SUBJID	VISITNUM	VISIT	SVSTDTC	SVENDTC
1001	20	Visit 20	2021-10-01	2021-10-03



Data Scenario 2 – Translation error

On average, during the past week, how bad were your asthma symptoms when you **woke up in the morning**?

0 = no symptoms

1 = very mild symptoms

2 = mild symptoms

3 = moderate symptoms

4 = quite severe symptoms

5 = severe symptoms

6 = very severe symptoms

औसतन, पिछले सप्ताह के दौरान, आपके अस्थमा के लक्षण कितने बुरे थे जब **आप रात में जागते थे प्रभात**?

0 = कोई लक्षण नहीं

1 = बहुत हल्के लक्षण

2 = हल्के लक्षण

3 = मध्यम लक्षण

4 = काफी गंभीर लक्षण

5 = गंभीर लक्षण

6 = बहुत गंभीर लक्षण

- ❖ Identified the issue lately
- ❖ Data cannot be changed hence assumed to be missing for analyses
- ❖ Impact to programming logic



Data Scenario 3 – Duplicate records due to device synchronization issue

SUBJID	RETESTCD	REORRES	REORRESU	REDTC	RETPTN
1001	PEF	350	ml	2017-07-01T10:00	1
1001	PEF	350	ml	2017-07-01T10:00	1
1001	PEF	348	ml	2017-07-01T18:00	2
1001	PEF	348	ml	2017-07-01T18:00	2

Listings were impacted as programs were developed considering one record per subject, per parameter, per timepoint


Data Scenario 4 – When device was replaced

Protocol: xxxxxxxx

Population: Intent-to-Treat

Figure x.x

Mean Change from Baseline in AM PEF(L/min) On- and Post- Treatment



Missing Data – A big pain point for analyses

- Missing data can lead to bias and lack of precision in statistical analyses
- Types of missing data (*Rubin 1976*)
 - I. Missing Completely at Random (MCAR): No relationship between the pattern of missing data
 - II. Missing at Random (MAR): Has a relationship with observed but not to a missing data
 - III. Missing Not at Random (MNAR): Has a relationship on how data is missing. Difficult to know the true nature of missing data
- Ways of dealing with missing data, recently most used and widely accepted is **Multiple Imputation**
- Creates multiple predictions for each missing value, considered uncertainty in the imputations and yield more accurate standard errors



Handling missing data - Multiple Imputation Process

Reference: CDSIC Analysis Data Model Implementation Guide

Step 1: Multiple Imputation

Create multiple dataset in which all plausible values for each missing data are imputed. SAS procedure used is PROC MI, created the dataset containing multiple imputation including original data. The iterations are indexed with the variable `_IMPUTATION_`

Step 2: Analyze

The analyses of the output dataset from Step 1 can be done using any desired statistical procedure and capture the resulting statistical estimates

Step 3: Combine to generate result

These estimates are based on the pooling of estimates from the multiple imputation dataset that are used to evaluate statistical significance. PROC MIANALYZE combines the result from every `_IMPUTATION_` iteration created using MI procedure



Multiple Imputation – Data submission

Reference: CDSIC Analysis Data Model Implementation Guide

In ADaM, the documentation of derived variables via variable level metadata, and statistical results via analysis results metadata, is paramount to achieving the concept of traceability. However, documenting the traceability of estimates created via multiple imputation cannot be achieved with these current metadata methods. In addition, it would not be practical to include all datasets that are created from the PROC MI process as part of a submission. To address traceability, the ADaM recommendation is to provide the program statements from the 3 procedures mentioned above as a part of the analysis results metadata. This allows the reviewer to re-create the analysis as desired. Of primary importance is to ensure that the options used in PROC MI—specifically the value of the seed, the number of iterations, and the method used for imputation—are clearly denoted.

- ❖ Multiple Imputation procedure takes time to run
- ❖ Ideal way is to create the imputation dataset for output generation
- ❖ This also helps for pooled analyses (ISE)
- ❖ Refer 2022 CDSIC EU Connect ADaM Traceability <https://wiki.cdisc.org/display/ITAUG/2022-06-29?preview=%2F153066587%2F153066585%2F2022-CDISC-Eu-ADaMTraceability-SFaini.pdf>



Regulatory Considerations



FDA recommendation to implement backup plan if there are any malfunctions with the electronic devices



FDA recommendation to reduce variations in instrument format and functionality from one device to another in case of BYOD usage



Sponsor should develop separate device-related respondent instructions and training materials for FDA review while switching from paper to electronic data collection mode



Sponsor should also submit equivalency test result to support measurement equivalence between paper and electronic COAs



Sponsor should submit any device usability testing and result, screen shot of the instrument, site training materials, **Raw score** if collected and **Derived score** in SDTM and ADaM



References

- (1) FDA: Methods to Identify What is Important to Patients & Select, Develop or Modify Fit-for-Purpose Clinical Outcomes Assessments <https://www.fda.gov/media/116277/download>
- (2) FDA: Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims <https://www.fda.gov/media/77832/download>
- (3) FDA's Roadmap to Patient Focused Outcome Measurement in Clinical Trials <https://nationalhealthcouncil.org/webinars/coa-series-fdas-roadmap-to-patient-focused-outcome-measurement-in-clinical-trials/>
- (4) Validation and equivalence of electronic clinical outcomes assessment systems, International Journal of Clinical Trials, Gary ST et al. *Int J Clin Trials*. 2020 Nov;7(4):271-277 <http://www.ijclinicaltrials.com>
- (5) Xtalks, Data Standards for eCOA in Clinical Trials <https://xtalks.com/webinars/data-standards-for-ecoa-in-clinical-trials/>



The Global Healthcare Data Science Community

Contact Channels

📞 UK +44 1843 609600
✉ office@phuse.global
🌐 phuse.global

Social Media

🐦 [@phusetwitta](https://twitter.com/phusetwitta)
📘 [/phusebook](https://facebook.com/phusebook)
📺 [/phusetube](https://youtube.com/phusetube)
🌐 [/company/phuse](https://company.phuse)